• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Theratechnologies Announces Completion of Acquisition by Future Pak

    9/25/25 1:21:35 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THTX alert in real time by email

    MONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today the completion of the previously-announced plan of arrangement under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"), pursuant to which the Purchaser has acquired all the issued and outstanding common shares of the Company (the "Shares") for US$3.01 per Share in cash plus one contingent value right ("CVR") per Share for additional aggregate cash payments of up to US$1.19 per CVR if certain milestones are achieved by the Company (the "Arrangement").

    Consideration for the Shares has been remitted by the Purchaser to Computershare Investor Services Inc., as depositary under the Arrangement, and will be paid to former shareholders of Theratechnologies as soon as reasonably practicable after the date hereof (or, in the case of registered shareholders, as soon as reasonably practicable after a properly completed and signed letter of transmittal is received by the depositary together with the share certificate(s) and/or DRS Advice(s) representing Shares formerly held by them).

    Each CVR is a contractual right that entitles the holder thereof to aggregate payments from the Purchaser of up to US$1.19 per CVR if certain milestones are achieved by the Company, the whole in accordance with the agreement entered into on the day hereof among the Purchaser, Future Pak and Computershare Trust Company of Canada as CVR agent. The CVRs are recorded in a register kept by the CVR agent and are not evidenced by a certificate or any other instrument. Based on a report prepared by an independent third-party valuator, the Company and the Purchaser have determined the fair market value of each CVR to be US$0.80 as at September 24, 2025.

    As a result of the completion of the Arrangement, it is expected that the Shares will be de-listed from the Toronto Stock Exchange on or about September 26, 2025 and from the Nasdaq Capital Market on or about September 25, 2025. The Company shall apply to cease to be a reporting issuer under Canadian securities laws in all provinces of Canada. The Company will also deregister the Shares under the U.S. Securities Exchange Act of 1934, as amended.

    Early Warning Reporting

    Immediately prior to the effective date of the Arrangement, the Purchaser and its affiliates did not own any Shares. An early warning report will be filed on SEDAR+ at www.sedarplus.ca under the Company's profile. Further information and/or a copy of the early warning report may be obtained from the contacts below. The Purchaser's head office is located at CB Biotechnology, LLC c/o Honigman LLP, 2290 First National Building, 660 Woodward Avenue, Detroit, MI 48226-3506.

    About Theratechnologies

    Theratechnologies (TSX:TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on its website at www.theratech.com.

    About Future Pak

    Founded in 1977 and headquartered in Wixom, Michigan, Future Pak, along with its affiliates, is a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products. Future Pak operates across retail, specialty and institutional markets, leveraging its robust infrastructure and partner network to deliver quality-first, patient-centric solutions.

    Forward-Looking Information

    This press release contains forward-looking statements and forward-looking information (collectively, "Forward-Looking Statements"), within the meaning of applicable securities laws, that are based on our management's beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as "may", "will", "if", "should", "could", "promising", "would", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the delisting of the Shares from the Toronto Stock Exchange and from the Nasdaq Capital Market, the Company ceasing to be a reporting issuer under Canadian securities laws in all provinces of Canada and the deregistration of the Shares under the U.S. Securities Exchange Act of 1934, as amended.

    These Forward-Looking Statements express, as of the date of this press release, the estimates, predictions, projections, expectations, or opinions of the Company about future events or results, as well as other assumptions, both general and specific, that the Company believes are appropriate in the circumstances. Although the Company believes that the expectations produced by these Forward-Looking Statements are founded on valid and reasonable bases and assumptions, these Forward-Looking Statements are inherently subject to important risks and uncertainties, many of which are beyond the Company's control, such that actual results may differ significantly from those that are disclosed in or implied by such Forward-Looking Statements. The important risks and uncertainties include, but are not limited to, the possibility that the Shares will not be delisted from the Toronto Stock Exchange or the Nasdaq Capital Market within the timing currently contemplated, that the Shares may not be delisted at all, due to failure to satisfy, in a timely manner or otherwise, conditions necessary for the delisting of the Shares or for other reasons, that the Company's application to cease to be a reporting issuer under applicable Canadian securities laws may not be accepted or may be delayed and that the Company may fail to achieve any milestones relating to the CVRs.

    Readers are cautioned that the foregoing list of factors is not exhaustive and undue reliance should not be placed on Forward-Looking Statements. As a result, readers are advised that actual results may differ materially from expected results. Unless otherwise required by applicable securities laws, the Company expressly disclaims any intention, and assumes no obligation to update or revise any Forward-Looking Statements whether as a result of new information, future events or otherwise.

    For further information, please contact:

    Future Pak

    Investors and media may contact [email protected].



    Primary Logo

    Get the next $THTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THTX

    DatePrice TargetRatingAnalyst
    11/17/2022$9.00Overweight
    Cantor Fitzgerald
    7/29/2021$8.00 → $3.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $THTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Theratechnologies Announces Completion of Acquisition by Future Pak

    MONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today the completion of the previously-announced plan of arrangement under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"), pursuant to which the Purchaser has acquired all the issued and outstanding common shares of the Company (the "Shares") for US$3.01 per Share in cash plus one contingent value right ("CVR") per Share for additional aggregate cash payments of up to US$1.19 per CVR if

    9/25/25 1:21:35 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak

    MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that the Company has obtained the final order from the Superior Court of Québec (Commercial Division) approving the previously-announced plan of arrangement (the "Arrangement") under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"). This final court approval follows the approval of the Arrangement by the shareholders of the Company at the special meeting of shareholders held on Septe

    9/16/25 5:10:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak

    MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the previously announced plan of arrangement (the "Arrangement") under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"). At the special meeting of shareholders of Theratechnologies held earlier today, the arrangement resolution was approved by 97.44% of the votes cast by the holders of shares present in person or virtually or represented by

    9/12/25 11:23:24 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Theratechnologies with a new price target

    Cantor Fitzgerald initiated coverage of Theratechnologies with a rating of Overweight and set a new price target of $9.00

    11/17/22 7:27:25 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Theratechnologies from Buy to Hold and set a new price target of $3.00 from $8.00 previously

    7/29/21 9:53:58 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity reiterated coverage on Theratechnologies with a new price target

    Canaccord Genuity reiterated coverage of Theratechnologies with a rating of Buy and set a new price target of $8.00 from $7.00 previously

    4/19/21 9:31:33 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    SEC Filings

    View All

    SEC Form 25-NSE filed by Theratechnologies Inc.

    25-NSE - Theratechnologies Inc. (0001512717) (Subject)

    9/25/25 4:08:58 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Theratechnologies Inc.

    6-K - Theratechnologies Inc. (0001512717) (Filer)

    9/25/25 2:02:29 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Theratechnologies Inc.

    6-K - Theratechnologies Inc. (0001512717) (Filer)

    9/17/25 10:10:03 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Leadership Updates

    Live Leadership Updates

    View All

    Theratechnologies Appoints Elina Tea to its Board of Directors

    MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and as a member of the Company's Audit Committee. Ms. Tea will be Investissement Québec's designee pursuant to its investor rights agreement with the Company. "Elina Tea's extensive experience in finance, corporate strategy, and investor relations makes her a valuable addition to our Board of Directors," said Dawn Svoronos, Chair of the Board o

    4/5/24 11:00:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Appoints Jordan Zwick to its Board of Directors

    MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and as a member of the Company's Audit Committee. "We welcome Jordan Zwick to the Board as an important addition to our esteemed group of advisors," said Dawn Svoronos, Chair of the Board of Directors at Theratechnologies. "With his extensive experience in the U.S. biotech and pharmaceutical industry, coupled with expertise in global

    3/21/24 8:00:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

    MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from the Board of Directors of Theratechnologies and as a member of its Audit Committee, effective immediately. "I want to thank Alain for his contributions to Theratechnologies as a director since joining the Company in October 2020 and for completing the annual review for the 2023 fiscal year", said Dawn Svoronos, Chair of the Board at Theratechnologies. "Alain was the current Chair of the Audit Committee

    2/29/24 4:34:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Financials

    Live finance-specific insights

    View All

    Theratechnologies Reports Financial Results for the Second Quarter 2025

    Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the second quarter 2025, ended May 31, 2025. All figures are in U.S. dollars unless otherwise stated. "Demand for EGRIFTA SV® remains very strong and we are witnessing

    7/9/25 7:30:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies to Announce Second Quarter 2025 Financial Results

    MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on Wednesday, July 9, 2025. Given the announcement of July 2, 2025, concerning the acquisition of the Company, a conference call will not be held. About Theratechnologies Theratechnologies (TSX:TH) (NASDAQ:THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is availabl

    7/3/25 5:30:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

    Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per shareUpfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date prior to announcement of Future Pak's initial non-binding proposalTransaction with Future Pak represents culmination of sale process whereby Theratechnologies solicited interest from a number of potential counterpartiesBoard unanimously recommends that shareholders approve the transaction MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage bio

    7/2/25 10:11:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Theratechnologies Inc.

    SC 13G - Theratechnologies Inc. (0001512717) (Subject)

    2/14/24 4:51:41 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Theratechnologies Inc. (Amendment)

    SC 13G/A - Theratechnologies Inc. (0001512717) (Subject)

    2/7/24 6:55:18 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Theratechnologies Inc.

    SC 13D - Theratechnologies Inc. (0001512717) (Subject)

    11/28/23 4:52:43 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care